Nodular Prurigo Market Report 2026

The nodular prurigo market size has grown strongly in recent years. It will grow from $1.25 billion in 2025 to $1.33 billion in 2026 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to increasing prevalence of chronic dermatological disorders, limited effectiveness of conventional topical therapies, growing awareness of pruritic skin diseases, expansion of dermatology specialty clinics, improved diagnostic recognition of nodular prurigo.

The nodular prurigo market size is expected to see strong growth in the next few years. It will grow to $1.7 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to rising development of novel biologics and monoclonal antibodies, increasing focus on personalized dermatology treatments, growing investments in inflammatory skin disease research, expansion of advanced immunotherapy pipelines, increasing demand for long-term itch control solutions. Major trends in the forecast period include increasing adoption of targeted immunomodulatory therapies, rising use of biologic treatments for chronic pruritus, growing focus on neuropathic itch management, expansion of long-term disease management protocols, enhanced emphasis on patient-centric dermatology care.

The rising demand for targeted therapies is expected to drive the growth of the nodular prurigo market in the coming years. Targeted therapies are medical treatments designed to specifically interfere with molecular pathways involved in disease development and progression. The increasing demand for these therapies is fueled by their ability to deliver more precise treatment with fewer side effects, enhancing patient outcomes and providing alternatives to traditional, less specific treatments. Nodular prurigo contributes to the development of targeted therapies by presenting a clear unmet medical need involving specific immune pathways, including IL-4, IL-13, and IL-31, allowing the use of biologics that precisely block these inflammatory signals for more effective management. For instance, in January 2024, according to the American Society of Gene & Cell Therapy, a US-based organization for gene and cell therapy, the number of gene therapies in Phase III increased by 10% in Q4 2023 compared with the previous quarter, marking the first rise since Q3 2022. Therefore, the increasing demand for targeted therapies is driving growth in the nodular prurigo market.

Key companies operating in the nodular prurigo market are focusing on developing innovative solutions, such as anti-IL-31 receptor biologics, to meet the growing demand for disease-modifying therapies that alleviate intense chronic itch, promote nodule resolution, and reduce dependence on long-term topical corticosteroids and broad immunosuppressants. An anti-IL-31 receptor monoclonal antibody is a biologic therapy made of engineered humanized antibodies that bind to IL-31 receptor A on sensory and immune cells, blocking IL-31 signaling, which is involved in chronic pruritus. For example, in August 2024, Galderma S.A., a Switzerland-based dermatology pharmaceutical company, launched Nemluvio (nemolizumab), an innovative anti-IL-31 receptor monoclonal antibody for adults with prurigo nodularis. Nemluvio is a humanized monoclonal antibody administered via subcutaneous injection that binds IL-31 receptor A to interrupt itch signaling and downstream inflammatory pathways. It was developed to reduce severe chronic itch and facilitate healing of pruritic nodules and is supplied as an autoinjector for outpatient use. Its unique features include a targeted mechanism, systemic activity suitable for widespread disease, and a dosing format designed to enhance patient adherence compared with clinic-only infusions.

In April 2024, Incyte Corporation, a US-based pharmaceutical company, partnered with China Medical System Holdings Limited to advance treatments for various autoimmune and inflammatory dermatologic conditions, including non-segmental vitiligo, hidradenitis suppurativa, prurigo nodularis, asthma, and chronic spontaneous urticaria. China Medical System Holdings Limited is a Hong Kong-based pharmaceutical company involved in nodular prurigo treatment.

Major companies operating in the nodular prurigo market are Merck and Co Inc, Sanofi SA, GlaxoSmithKline plc, Amgen Inc, Regeneron Pharmaceuticals Inc, Astellas Pharma Inc, Sun Pharmaceutical Industries Limited, Galderma SA, Incyte Corporation, Kyowa Kirin Co Ltd, LEO Pharma AS, Maruho Co Ltd, Kiniksa Pharmaceuticals Ltd, Keymed Biosciences Co Ltd, Trevi Therapeutics Inc, Menlo Therapeutics Inc, VYNE Therapeutics Inc, Celldex Therapeutics Inc, AbbVie Inc, Pfizer Inc, Novartis AG, Eli Lilly and Company.

North America was the largest region in the nodular prurigo market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nodular prurigo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nodular prurigo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the nodular prurigo market by increasing costs associated with imported biologic drugs, advanced pharmaceutical ingredients, diagnostic reagents, and specialized medical devices used in long-term disease management. North America and Europe are most affected due to dependence on cross-border pharmaceutical manufacturing and biologic supply chains, while Asia-Pacific faces cost pressures related to clinical trial materials and specialty drug imports. These tariffs are contributing to higher treatment costs and slower adoption of newer therapies. However, they are also encouraging regional drug manufacturing, local clinical research expansion, and domestic production of advanced dermatological therapeutics.

The nodular prurigo market research report is one of a series of new reports that provides nodular prurigo market statistics, including nodular prurigo industry global market size, regional shares, competitors with a nodular prurigo market share, detailed nodular prurigo market segments, market trends and opportunities, and any further data you may need to thrive in the nodular prurigo industry. This nodular prurigo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Nodular prurigo, also known as prurigo nodularis, is a chronic skin condition characterized by intensely itchy, firm nodules that commonly appear on the arms, legs, and torso. The condition involves a combination of immune, nerve, and inflammatory factors, where persistent itching leads to excessive scratching, worsening the lesions and causing scarring. Nodular prurigo typically requires long-term dermatological management.

The primary types of nodular prurigo include chronic nodular prurigo, acute nodular prurigo, and subacute nodular prurigo. Chronic nodular prurigo is a long-lasting form marked by the development of intensely itchy, firm nodules or bumps on the skin. Treatments include topical therapies, systemic medications, phototherapy, and immunosuppressants. The condition affects various patient demographics, including adults, children, and the elderly, and treatment is provided by end users such as hospitals, specialty clinics, homecare providers, and others.

The nodular prurigo market consists of revenues earned by entities by providing services such as diagnosis and clinical evaluation, prescription of topical treatments, phototherapy, biologic therapies, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The nodular prurigo market also includes sales of products including oral antidepressants, JAK inhibitors, and topical calcineurin inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.